Bladder Cancer

• Multifocal field carcinogenesis and carcinogen-induced urothelial transformation: Chronic exposure to carcinogens (tobacco smoke, occupational chemicals) or their metabolites causes widespread DNA damage across the urothelium. These carcinogens are concentrated in urine, delivering prolonged mutagenic exposure to bladder epithelium. The urothelium undergoes malignant transformation through dysplasia (low-grade and high-grade) with accumulation of oncogenic mutations. This explains both the multifocal nature of bladder cancer and the field effect phenomenon where even anatomically distant residual urothelium retains carcinogenic potential, justifying surveillance cystoscopy.

• Two distinct molecular pathways with different clinical trajectories: The low-grade, non-muscle-invasive pathway (approximately 70% of NMIBC) is driven by FGFR3 mutations and RAS pathway activation, resulting in tumors with relatively good prognosis despite frequent recurrence. Conversely, the high-grade invasive pathway (approximately 90% of MIBC and 30% of high-grade NMIBC) involves TP53 and RB inactivation, PTEN loss, and PIK3CA mutations, leading to aggressive tumor biology with propensity for muscle invasion and distant metastasis. This molecular heterogeneity explains the dramatically different recurrence and progression rates: low-grade NMIBC has <5% progression to muscle invasion at 5 years, while high-grade NMIBC progresses in 30-50% of cases.

• Loss of normal cell cycle checkpoints and increased genomic instability: Inactivation of p53 tumor suppressor (mutated in 40-50% of MIBC) eliminates G1/S checkpoint control, allowing cells with DNA damage to proceed through the cell cycle. Loss of RB protein function (50% of MIBC) abrogates another critical checkpoint. These changes permit uncontrolled proliferation and accumulation of additional mutations. Increased chromosomal instability results from defective DNA repair mechanisms, explaining the high mutational burden in bladder cancer and responsiveness to immune checkpoint inhibitors.

• Epithelial-mesenchymal transition (EMT) and invasion mechanisms: High-grade and muscle-invasive tumors undergo EMT, downregulating E-cadherin (loss of adherens junctions) and upregulating N-cadherin and vimentin, promoting detachment from the epithelium and acquisition of invasive properties. Upregulation of matrix metalloproteinases (MMP-2, MMP-9) degrades the extracellular matrix and basement membrane, facilitating invasion through the lamina propria and into the muscularis propria (detrusor muscle). Transcription factors like Snail and Slug drive these changes.

• Angiogenesis and hypoxia-driven progression: As tumors expand beyond a few millimeters, hypoxia develops within the tumor microenvironment. HIF-1α accumulation triggers VEGF upregulation, promoting neoangiogenesis essential for tumor growth beyond 1-2 mm. Inadequate perfusion creates selective pressure for cells with enhanced survival under hypoxic conditions, further driving malignant progression. This angiogenic dependence becomes clinically relevant in treatment decisions (anti-angiogenic agents) and prognosis (increased microvessel density correlates with worse outcomes).

• Immune evasion and immunotherapy resistance mechanisms: Bladder tumors evade immune surveillance through upregulation of PD-L1 on tumor and infiltrating immune cells, engagement of PD-1 on T cells, leading to T cell exhaustion. Additionally, tumors create an immunosuppressive microenvironment through recruitment of regulatory T cells (Tregs) and tumor-associated macrophages (TAMs). Conversely, some tumors maintain high mutational burden (especially with smoke exposure) and infiltration by CD8+ T cells, predicting response to immune checkpoint inhibitors. The immunotherapy-susceptible phenotype typically shows high PD-L1 expression, high mutational load, and Th1-polarized infiltrate.

• Molecular subtypes with prognostic implications: Integrated genomic analyses identify molecular subtypes: luminal tumors (resembling normal bladder urothelium, expressing uroplakin and E-cadherin, often low-grade), basal/squamoid tumors (expressing p63 and CK5/6, typically high-grade and aggressive), neuronal tumors, and unstable tumors. Luminal tumors respond better to hormone therapy approaches and traditional chemotherapy, while basal tumors show enhanced immunotherapy response.

• Cigarette smoking (40-50% of bladder cancer cases): Tobacco smoke contains over 70 known carcinogens including polycyclic aromatic hydrocarbons (PAH), nitrosamines, and aromatic amines (2-naphthylamine, 4-aminobiphenyl). After hepatic conjugation, these metabolites are renally cleared and concentrated in urine, directly exposing urothelium. Smokers have 3-4 fold increased risk compared to never-smokers, with dose-response relationship (pack-years of exposure). Importantly, former smokers retain elevated risk for 5-10 years after cessation due to persistent urothelial changes.

• Occupational chemical exposures: Workers in dye, textile, rubber, leather, and pesticide industries have documented increased bladder cancer risk. Aromatic amines (particularly 2-naphthylamine and benzidine) were historically used in dye manufacturing; exposure increases risk 10-50 fold with latency period of 15-40 years. Chlorination byproducts in drinking water (trihalomethanes) show weak associations in some studies. Occupational exposure now represents only 2-5% of cases due to regulatory controls in developed countries.

• Chronic irritation and inflammation: Chronic cystitis from recurrent infections increases risk. Schistosomiasis haematobium (endemic in parts of Africa and Middle East) causes chronic parasitic infection, leading to squamous cell carcinoma (rather than urothelial carcinoma), a critical board distinction. Neurogenic bladder from spinal cord injury with chronic catheterization dramatically increases risk; these patients develop aggressive squamous or adenocarcinomas. Indwelling catheters (self-catheterization vs permanent suprapubic catheters) represent independent risk factors through chronic mucosal injury and bacterial superinfection.

• Bladder exstrophy and intestinal cystoplasty: Patients with bladder exstrophy (congenital failure of bladder closure) have markedly elevated risk of adenocarcinoma if left unrepaired. Intestinal cystoplasty (bowel substitution cystoplasty for neurogenic bladder or other indications) carries 5-10% lifetime risk of malignancy, particularly adenocarcinoma, occurring 20-50 years post-operatively. These high-risk patients require surveillance.

• Prior pelvic radiation therapy: Patients irradiated for prostate, cervical, or gynecologic malignancies have 5-10 fold increased bladder cancer risk, typically developing 5-10 years after radiation. Radiation-induced urothelial injury, fibrosis, and chronic ischemia promote malignant transformation. Radiation-associated tumors tend to be more aggressive and present at advanced stages.

• Chemical cystitis agents: Cyclophosphamide, particularly in high cumulative doses used for lymphoma or autoimmune conditions, induces hemorrhagic cystitis and chronic urothelial damage, increasing malignancy risk 5-25 fold. The risk persists decades after treatment cessation. Acrolein, a toxic metabolite of cyclophosphamide, is the primary culprit; mesna (MESNA) co-administration provides some protection.

• Hereditary syndromes: Rare hereditary conditions increase susceptibility. Lynch syndrome (mismatch repair gene mutations) increases bladder cancer risk 20-100 fold. Individuals with BRCA2 mutations have modestly elevated risk. Hereditary papillary renal carcinoma (MET mutations) rarely associates with bladder cancer.

• Prior history of upper urinary tract urothelial carcinoma: Patients with renal pelvis or ureteral urothelial carcinoma have 30-50% risk of metachronous bladder cancer, reflecting field carcinogenesis across the entire urothelium.

• Recurrent urinary tract infections and bacteriuria: Some epidemiologic data suggest association with chronic cystitis, though distinguishing causal relationship from reverse causation (early tumors causing infection) remains difficult. Schistosomiasis is the clearest infection-associated risk factor.

• Age and sex: Incidence increases dramatically after age 55, with median age at diagnosis of 72 years. Men have 3-4 fold higher incidence, partially explained by higher smoking prevalence historically but not entirely accounted for; potential hormonal and sex-chromosome-linked factors may contribute.

• Race/ethnicity differences: Whites have highest incidence (20 per 100,000 annually), followed by African Americans (16 per 100,000), Hispanics, and Asian Americans, though mortality is highest in African Americans, possibly reflecting delayed diagnosis and reduced access to advanced therapies. Native Americans with chronic schistosomiasis exposure have exceptional risk in certain geographic areas.

• Painless gross hematuria (most common presenting symptom, 80-90% of cases): Hematuria occurs as tumor ulcerates through epithelium into microvasculature. The degree of hematuria varies from microscopic (found on urinalysis) to obvious blood clots in urine. In non-muscle-invasive disease, hematuria may be intermittent and relatively mild, potentially leading to delayed diagnosis if not taken seriously. The key clinical principle: any episode of gross hematuria in an adult (particularly men >40 years, women >50 years) warrants urologic evaluation including cystoscopy. Absence of dysuria or other urinary tract infection symptoms does not exclude bladder cancer; in fact, painless hematuria is more concerning for malignancy than hematuria with dysuria (suggesting infection).

• Lower urinary tract irritative symptoms: Increased urinary frequency, dysuria (pain with urination), and urgency occur in 20-30% of cases, primarily in muscle-invasive disease. These symptoms result from tumor-induced inflammation of bladder mucosa and reduced functional bladder capacity (from large tumors or diffuse carcinoma in situ). The combination of irritative symptoms with hematuria should heighten suspicion for malignancy. Urinary incontinence may develop, particularly with CIS (carcinoma in situ) affecting widespread urothelium.

• Flank pain and costovertebral angle (CVA) tenderness: Presents when tumor obstructs ureteral orifice, causing hydronephrosis. Results from either direct tumor invasion at the ureterovesical junction or from external compression. Unilateral hydronephrosis indicates muscle-invasive or locally advanced disease, signifying worse prognosis. Flank pain suggests upper tract involvement and impaired renal function.

• Suprapubic pain and pelvic pain: Common with muscle-invasive or locally advanced tumors invading bladder wall, pelvic sidewall, or adjacent organs. Pain is typically worse with bladder filling and may improve with urination. Anterior pelvic wall pain suggests anterior bladder wall invasion.

• Constitutional symptoms: Weight loss, anorexia, and malaise indicate advanced disease, often present in 20-30% of patients with metastatic disease. These nonspecific symptoms reflect systemic inflammatory response and metabolic effects of advanced malignancy.

• Obstructive lower urinary tract symptoms: Weak stream, hesitancy, and incomplete emptying occur with tumors invading the bladder neck or obstructing the proximal urethra. Increased post-void residual volume may result, increasing risk of urinary tract infection.

• Physical examination findings: Often unremarkable in early disease. Advanced disease may show suprapubic mass (palpable with large tumor), fixed pelvic mass (suggesting invasion), lymphadenopathy (regional lymph node involvement), lower extremity edema (from lymphatic obstruction), or hepatomegaly (liver metastases). Marked suprapubic tenderness suggests advanced local disease with peritoneal irritation. A distended bladder may be palpable with urinary retention from lower urinary tract obstruction.

• Important clinical variants:
• Carcinoma in situ (CIS): Presents with severe irritative symptoms (dysuria, frequency, urgency, nocturia) out of proportion to hematuria; may have microhematuria or no visible hematuria. CIS represents flat high-grade dysplasia confined to lamina propria without muscle invasion, yet carries significant risk of progression to invasive disease (30-50% at 5 years if untreated). Often multifocal and associated with poor prognosis despite superficial stage.
• Painless hematuria without other symptoms: Classic "red flag" presentation; must not be dismissed as "infection" without cystoscopic evaluation.
• Recurrent urinary tract infections with persistent pyuria despite adequate antibiotic therapy: May indicate underlying bladder cancer, especially if bacteria persist in urine cultures despite treatment.
• Incidental finding on imaging: Bladder masses occasionally discovered on CT or ultrasound done for other indications, especially when hematuria was previously unrecognized.

• History and risk factor assessment: Detailed inquiry into hematuria characteristics (gross vs microscopic, duration, persistence), associated lower urinary tract symptoms, and importantly, risk factor exposure (smoking, occupational history, prior pelvic radiation, cyclophosphamide exposure, schistosomiasis exposure, neurogenic bladder). Duration of symptoms correlates imperfectly with stage; even long-standing hematuria may represent advanced disease.

• Urinalysis with microscopy (sensitivity variable depending on grade and stage): Gross or microscopic hematuria is present in 80-90% of urothelial carcinomas. Pyuria (white blood cells) may be present, sometimes triggering empiric antibiotic treatment that delays diagnosis. Negative urine culture despite pyuria suggests possible malignancy rather than infection. Urine cytology has high specificity (95-98%) but lower sensitivity, particularly for low-grade tumors (sensitivity only 30-40% for low-grade disease, 70-80% for high-grade disease). Cytology is most useful for detecting high-grade disease and CIS and for surveillance of patients with prior bladder cancer history.

• Urine biomarkers: FDA-approved urine markers for bladder cancer detection include NMP22 (nucleosome-associated protein), BTA stat (bladder tumor antigen), and FISH for chromosomal abnormalities (UroVysion). These tests have improved sensitivity (50-85%) compared to cytology, particularly for low-grade tumors, but lower specificity (60-80%), meaning positive results require confirmation with cystoscopy. These markers are more useful for surveillance in patients with prior bladder cancer history (detecting recurrence) than for initial diagnosis. Newer molecular markers (methylated SEPT9, TDRD1) and tumor-associated mutations show promise but are not yet standard clinical practice.

• Cystoscopy (gold standard for diagnosis and staging of NMIBC): Direct visualization of bladder mucosa via rigid or flexible cystoscope allows identification of lesions, biopsy, and initial assessment of extent and location. Appearance varies: low-grade tumors typically appear as pale, papillary lesions with intact surface; high-grade tumors appear as nodular, sessile masses with friable surfaces and spontaneous bleeding. **CIS appears as

Immediate stabilisation

• Clot retention / gross hematuria: place a large-bore three-way catheter, evacuate clot, and start continuous bladder irrigation; transfuse for symptomatic anemia. Failure to clear clot or ongoing hemorrhage warrants urgent cystoscopy with fulguration.
• Obstructive uropathy: unilateral or bilateral hydronephrosis with rising creatinine requires decompression by ureteral stent or percutaneous nephrostomy before systemic therapy, since cisplatin eligibility depends on renal function.

Diagnostic and first-line therapy — all stages begin here

• Transurethral resection of bladder tumor (TURBT): both therapeutic and the staging procedure; the specimen must contain muscularis propria to exclude muscle invasion. The AUA/SUO non-muscle-invasive bladder cancer (NMIBC) guideline recommends repeat TURBT for high-grade T1 disease or when detrusor muscle is absent.
• Immediate single post-operative intravesical chemotherapy (antineoplastic instillation — gemcitabine or mitomycin C) within 24 hours of TURBT reduces recurrence in low- and intermediate-risk NMIBC (AUA/SUO).
• Intravesical BCG (live attenuated Mycobacterium bovis, inducing a local Th1 immune response) with induction plus maintenance is standard for high-risk NMIBC — high-grade Ta, T1, or carcinoma in situ (AUA/SUO).

Escalation and second line

• BCG-unresponsive NMIBC: radical cystectomy is preferred; bladder-sparing alternatives include a PD-1 inhibitor (pembrolizumab) or intravesical gene therapy in selected patients (NCCN).
• Muscle-invasive disease (MIBC): neoadjuvant cisplatin-based combination chemotherapy (dose-dense MVAC or gemcitabine–cisplatin) followed by radical cystectomy with bilateral pelvic lymphadenectomy and urinary diversion (ileal conduit or orthotopic neobladder) — AUA/ASCO/ASTRO/SUO and NCCN. Trimodal therapy (maximal TURBT plus chemoradiation with a radiosensitizer) is an option for selected solitary tumors without extensive CIS or hydronephrosis.
• Metastatic disease: an antibody–drug conjugate plus checkpoint inhibitor (enfortumab vedotin with pembrolizumab) is NCCN-preferred first line; platinum-based chemotherapy with avelumab maintenance and FGFR-targeted therapy (erdafitinib) for FGFR2/3-altered tumors are alternatives.

Contraindicated

• BCG after traumatic catheterization, with gross hematuria, active UTI, or immunosuppression — risk of disseminated BCG infection.
• Cisplatin with impaired creatinine clearance, hearing loss, neuropathy, or poor performance status; carboplatin is not an equivalent neoadjuvant substitute.
• Delaying cystectomy for repeated intravesical courses in BCG-unresponsive high-grade disease.

Disease-related

• Clot retention and hemorrhagic shock (emergency): tumor erosion into mucosal vessels; signalled by inability to void with a distended, tender bladder or by hypotension with falling hemoglobin.
• Obstructive uropathy and post-renal AKI (emergency if bilateral or anuric): tumor at the ureterovesical junction blocks urine outflow; flank pain, hydronephrosis on imaging, rising creatinine, and hyperkalemia.
• Vesicovaginal or enterovesical fistula: transmural invasion or radiation necrosis; pneumaturia and fecaluria or continuous vaginal urine leakage.
• Metastatic complications: bone metastases cause pain, hypercalcemia, and malignant spinal cord compression (emergency — back pain with weakness or saddle anesthesia; urgent MRI and glucocorticoids). Venous thromboembolism risk is elevated in advanced disease.

Treatment-related

• TURBT: bladder perforation (extravasation, peritonism), post-operative hemorrhage, and dilutional hyponatremia from absorption of hypotonic irrigant — confusion or seizure.
• BCG toxicity: irritative voiding and low-grade fever are expected; disseminated BCG infection/BCG sepsis (emergency) presents with high fever, rigors, and hypotension after instillation, often following traumatic catheterization, and is treated with antimycobacterial therapy (isoniazid, rifampin, ethambutol) plus corticosteroids. Granulomatous prostatitis or hepatitis may follow.
• Intravesical mitomycin C: chemical cystitis and contact dermatitis of the palms/genitals.
• Cisplatin: nephrotoxicity, ototoxicity, peripheral neuropathy, and severe emesis — check audiometry and creatinine clearance before each cycle.
• Immune checkpoint inhibitors: immune-related colitis, hypophysitis, thyroiditis, pneumonitis, and myocarditis (emergency — troponin rise with arrhythmia); high-grade events require holding the drug and giving corticosteroids.
• Enfortumab vedotin: severe cutaneous reactions including Stevens-Johnson syndrome/TEN (emergency), hyperglycemia, and neuropathy.
• Urinary diversion: an ileal conduit or neobladder reabsorbs urinary ammonium and chloride, producing a hyperchloremic normal anion gap metabolic acidosis; terminal ileal resection causes vitamin B12 deficiency years later. Ureteroenteric stricture, stomal stenosis, and pyelonephritis are late structural complications.
• Pelvic radiation: radiation cystitis with reduced bladder capacity and late hemorrhagic cystitis.

• Painless gross hematuria in an adult smoker is bladder cancer until proven otherwise: the single best next step is cystoscopy plus upper-tract imaging with CT urography — not empiric antibiotics, not a repeat urinalysis. Per the AUA/SUO microhematuria guideline, even a single episode of gross hematuria mandates cystoscopic evaluation regardless of anticoagulant use.
• Histology follows the exposure: urothelial (transitional cell) carcinoma with smoking or aromatic amines; squamous cell carcinoma with Schistosoma haematobium or chronic indwelling catheter; adenocarcinoma with a urachal remnant at the bladder dome or bladder exstrophy. This is the single most tested association.
• Cyclophosphamide → acrolein → hemorrhagic cystitis → later urothelial carcinoma; mesna and hydration prevent the cystitis but the malignancy risk persists for decades.
• The TURBT specimen must contain muscularis propria — without detrusor in the sample you cannot call a tumor non-muscle-invasive, and staging (not grade alone) drives every subsequent decision.
• Intravesical BCG is immunotherapy, not an antibiotic: it is used for high-grade Ta, T1, and carcinoma in situ. Fever with rigors and hypotension hours after instillation is disseminated BCG, treated with antituberculous drugs plus steroids — a classic stem that punishes the reflex answer of broad-spectrum antibacterials alone.
• Muscle-invasive disease gets neoadjuvant cisplatin-based chemotherapy before radical cystectomy (AUA/ASCO/ASTRO/SUO); going straight to surgery, or substituting carboplatin in the neoadjuvant setting, is the common distractor.
• New non-anion-gap metabolic acidosis in a patient with an ileal conduit reflects reabsorption of urinary ammonium chloride by intestinal mucosa, not sepsis or renal tubular disease.
• Distractors to avoid: hematuria plus flank pain plus a palpable mass points to renal cell carcinoma; hematuria with dysuria and positive culture suggests cystitis — but sterile pyuria that persists after antibiotics should send you back to cystoscopy. Never attribute painless hematuria in an older man to benign prostatic hyperplasia.